SenzaGen moves into their new laboratories at Medicon Village

In June, SenzaGen moves into its new lab facilities at Medicon Village in Lund. As SenzaGen is expanding, establishing new partnerships and customers and is hiring more staff, the company has a demand to set up in new premises and gather the business. The lab is completely new and is equipped with the latest technology to implement the tests.

– The new lab is a natural step in SenzaGen’ss commercialization of what we have developed here at the department of Immunotechnology. Research and development is continuing at LTH, says Malin Lindstedt , founder and CSO of SenzaGen .

The opening of the lab was celebrated with new and old colleagues as well as investors, owners and business partners of SenzaGen.

diplom

SenzaGen wins innovation prize SKAPA and is appointed as provincial finalist

SenzaGen has won yet another award and was recently appointed the provincial finalist in Skåne and will thereby have the opportunity to win the national innovation award SKAPA, the country’s largest and most prestigious innovation prize. The SKAPA Prize is awarded to innovators in order to support the commercialization of their products.

The prize is awarded by the Foundation SKAPA in cooperation with ALMI. It is the regional ALMI companies in cooperation with local inventors’ associations affiliated to the Swedish Inventors Association which has chosen the county finalists for the award.

The appointment means that SenzaGen have the opportunity to be appointed Swedish champion of innovation. As the county finalist, SenzaGen receives a prize worth SEK 25 000 with the option to gain an additional SEK 550 000 (maximum spread over three laureates) if they succeed as winners of the national prize.

– SenzaGen has been able to package advanced research in a transparent, commercial way and have in a short time shown that they will be able to both significantly minimize the number of animal tests  being performed and deliver a better accuracy in the tests and hence a better value to their customers. It is going to be very exciting to follow the company in the future! says Johan Olsen, ALMI

The national final is being held on 5 Nov 2015 in Stockholm.

Almi Invest awards SenzaGen the prestigeous Annual Keywhole investment prize. “Årets titthålsinvestering”

– The investment will be used to sharpen Senzagen business model and develop software linked to cell-based in vitro assays, says Anki Malmborg Hager, CEO at SenzaGen.

Press reslease at ALMI’s newsdesk

Hanna Frykman new Market Coordinator at SenzaGen

SenzaGen continues its expansion and is setting up a sales and marketing organisation. In this process SenzaGen recruits Hanna Frykman as a marketing coordinator.

Most recently, Hanna comes from the Royal Academy of Sciences, where she worked as an information coordinator and scientific secretary of an EU project. Hanna has experience as communicator and project manager, and has been working with startup companies. She is one of the developers of the cultural business project Thomanders Jul in Lund.

– It is extremely exciting to be working with a company in this early stage and to build up the business from scratch, says Hanna Frykman.

Hanna begins in SenzaGen in March 2015 and will focus on developing graphical profile and work with sales and marketing at SenzaGen.

– The combination of science and business thinking and her ability to build up network was been instrumental in the recruitment of Hanna. I very much look forward to working together with Hanna, says Anki Malmborg Hager, CEO of SenzaGen

Maria Agemark new quality manager at SenzaGen

SenzaGen is in an expansive phase and is building up its team with new personnel. Maria Agemark has been recruited as quality manager and was previously working at the Department Immunotechnology at LTH . Maria has a PhD in biochemistry, where she conducted research on the Aquaporins in humans and plants.

– It is going to be exciting and challenging to work in a new company that is in an exciting early phase. I know the research behind the products well and look forward to be part of the new team that SenzaGen is setting up, says Maria Agemark .

Maria starts on SenzaGen in March 2015 and will focus on building up the new lab and quality systems.

– Maria has an expertise that we need to bring the company to the next level. I very much look forward to working together with Maria, says Anki Malmborg Hager, CEO of SenzaGen.

blue senzagen logo

SenzaGen receives financial support

SenzaGen is proud to be awarded financial support by IKS Accelerator.

Signature biomarker analysis for prediction of skin sensitizers using a cell-based in vitro alternative to animal experimentation

Henrik Johansson, Ann-Sofie Albrekt, Carl A.K. Borrebaeck, Malin Lindstedt
Department of Immunotechnology, Lund University, BMC D13, 21184 Lund, Sweden

Introduction
Allergic contact dermatitis is an inflammatory skin disease caused by immunological responses towards chemical haptens. Current test of sensitizing chemicals rely on animal experimentation. New legislations on the registration and use of chemicals within pharmaceutical and cosmetic industries have stimulated significant research efforts to develop alternative, human cell-based assays for the prediction of sensitization.
We have developed a novel cell-based assay for the prediction of sensitizing chemicals, based on differentially regulated transcripts in the myeloid cell-line MUTZ-3.

 

Conclusions
We have identified a biomarker signature with accurate predictive power, which represents a compelling readout for an in vitro assay useful for the identification of human sensitizing chemicals. The biomarker signature include transcripts involved in relevant biological pathways, such as oxidative stress and xenobiotoic induced responses, which sheds light on the molecular interactions involved in the process of sensitization.

Poster:

Signature biomarker analysis for prediction of skin sensitizers using a cell-based in vitro alternative to animal experimentation_EAACI 2011 LTH_p